Skip to main content
Premium Trial:

Request an Annual Quote

Ventana Strikes Deal to Develop CDx for Incyte's Cancer Drugs

NEW YORK (GenomeWeb News) – Roche's Ventana Medical Systems today announced a collaboration to develop companion diagnostics for Incyte's oncology drug programs.

The first test will be developed for Incyte's ID01 inhibitor program, Ventana said, adding it will support Incyte's efforts using its expertise in companion diagnostics, immunohistochemistry technology platforms, and customer support.

Financial and other terms of the deal were not disclosed.

"With the advancement of INCB24360 into multiple Phase II studies, our first-in-class IDO1 inhibitor program was a logical place to begin to incorporate potential companion diagnostics," Victor Sandor, Incyte's group vice president, clinical development, said in a statement.

The agreement follows a deal between Ventana and Boehringer Ingelheim to develop companion diagnostics for cancer drugs in the German drug firm's pipeline. In September, Chinese regulators approved Ventana's ALK immunohistochemistry assay as a companion diagnostic for Pfizer's Xalkori (crizotinib) therapy.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.